The Yield Growth Corp. (CSE:BOSS, OTCQB:BOSQF, FSE:YG3) is pleased to announce that its Urban Juve Lip Balm with Hemp Oil can now be sold in the European market. Urban Juve’s Responsible Person in Europe, Biorius, has issued a compliance certificate for the product in accordance with EU regulations.

yield growth


Urban Juve Lip Balm with Hemp Oil approve for sale in Europe

Urban Juve’s Lip Balm with Hemp Oil is one of the brand’s top-selling products. The lip balm will be featured in Vogue Beauty Highlights in the October issue of UK Vogue, introducing the product to a new audience of 4.1 million readers. The lip balm will also be included in the gift bag at the ipsy Live event in New York this coming October, which will be well-attended by the beauty industry elite. Urban Juve is now manufacturing 250,000 units of its lip balm, which will be ready in September for sampling, retail sales, and e-commerce.

“We are excited about the new design of our Ultra-Hydrating Lip Balm and can’t wait to share it with hundreds of thousands of consumers through sampling and sales,” says Penny Green, CEO of Yield Growth and Urban Juve. “Through our engagement with top design agencies in New York, we are now planning a photo shoot and campaign that will showcase the Urban Juve products internationally this fall.”

Pursuant to EU regulations, Yield Growth retained Biorius to act as its Responsible Person for Urban Juve. In order to sell cosmetic products in the European Union, the Responsible Person must first issue a compliance certificate for each product. After a rigorous review of each ingredient in the lip balm, including Urban Juve’s proprietary hemp root oil, Biorius issued a certificate of compliance, confirming that Urban Juve Ultra Hydrating Lip Balm is now registered with the EU. Urban Juve now has two products registered with the EU and expects to have nine more products registered by early fall.

As proposed legislation across the European Union continues to bring cannabis closer to the mainstream, high-end cannabis products are gaining in popularity. With a total population over 508 million, the EU represents massive market potential for Urban Juve products.

About The Yield Growth Corp.

The Yield Growth Corp. develops, manufactures and distributes cannabis and hemp infused luxury product brands Urban Juve and Wright & Well and has a catalogue of over 200 wellness and beauty products in development. It intends to disrupt the international wellness market, which is a $4.2 Trillion Global Economy, according to the Global Wellness Institute, by connecting ancient healing with modern science and technology. Its management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, M·A·C Cosmetics, Skechers, Best Buy, Aritzia, Coca-Cola and Pepsi Corporation. Yield Growth serves mainstream luxury consumers who seek sophisticated wellness products. Its flagship consumer brand, Urban Juve, has proprietary, patent-pending hemp root oil extraction technology and formulas. Yield Growth is building sophisticated international distribution channels and has multiple revenue streams including licensing, services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visitwww.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny Green, President & CEO
Kristina Pillon, Investor Relations
invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677
1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve and Wright & Well products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Click here to connect with Yield Growth Corp. (CSE:BOSS) for an Investor Presentation.

Source: www.newsfilecorp.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less